Common Contracts
4 similar Merger Agreement contracts by Arco Platform Ltd., Myovant Sciences Ltd., Sumitomo Chemical Co., Ltd., Urovant Sciences Ltd.
AGREEMENT AND PLAN OF MERGER by and among ACHIEVE HOLDINGS, ACHIEVE MERGER SUB, and ARCO PLATFORM LIMITED Dated as of August 10, 2023Merger Agreement • August 11th, 2023 • Arco Platform Ltd. • Services-educational services • Delaware
AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of August 10, 2023 (the “Agreement Date”), by and among Arco Platform Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), Achieve Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“Parent”), and Achieve Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned Subsidiary of Parent (“Merger Sub”). Parent, Merger Sub and the Company are each sometimes referred to herein as a “Party” and collectively as the “Parties.” Certain capitalized terms used in this Agreement are defined in Section 9.03.
AGREEMENT AND PLAN OF MERGER by and among SUMITOVANT BIOPHARMA LTD., ZEUS SCIENCES LTD., MYOVANT SCIENCES LTD. and, solely with respect to Article IX and Annex A, SUMITOMO PHARMA CO., LTD. Dated as of October 23 , 2022Merger Agreement • October 24th, 2022 • Myovant Sciences Ltd. • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of October 23 , 2022 (the “Agreement Date”), by and among Myovant Sciences Ltd., a Bermuda exempted company limited by shares (the “Company”), Sumitovant Biopharma Ltd., a Bermuda exempted company limited by shares (“Parent”), Zeus Sciences Ltd., a Bermuda exempted company limited by shares and a wholly owned Subsidiary of Parent (“Merger Sub”), and, solely with respect to Article IX and Annex A hereof, Sumitomo Pharma Co., Ltd., a company organized under the laws of Japan (“SMP”). Parent, Merger Sub and the Company are each sometimes referred to herein as a “Party” and collectively as the “Parties.” Certain capitalized terms used in this Agreement are defined in Annex A.
AGREEMENT AND PLAN OF MERGER by and among SUMITOVANT BIOPHARMA LTD. TITAN LTD., UROVANT SCIENCES LTD. and, solely with respect to Section 9.13, SUMITOMO DAINIPPON PHARMA CO., LTD. Dated as of November 12, 2020Merger Agreement • November 13th, 2020 • Urovant Sciences Ltd. • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of November 12, 2020 (the “Agreement Date”), by among Urovant Sciences Ltd., a Bermuda exempted company limited by shares (the “Company”), Sumitovant Biopharma Ltd., a Bermuda exempted company limited by shares (“Parent”), Titan Ltd., a Bermuda exempted company limited by shares and a wholly owned Subsidiary of Parent (“Merger Sub”) and, solely with respect to Section 9.13 hereof, Sumitomo Dainippon Pharma Co., Ltd., a company organized under the laws of Japan (“Sumitomo”). Parent, Merger Sub and the Company are each sometimes referred to herein as a “Party” and collectively as the “Parties.” Certain capitalized terms used in this Agreement are defined in Section 9.03.
AGREEMENT AND PLAN OF MERGER by and among SUMITOVANT BIOPHARMA LTD. TITAN LTD., UROVANT SCIENCES LTD. and, solely with respect to Section 9.13, SUMITOMO DAINIPPON PHARMA CO., LTD. Dated as of November 12, 2020Merger Agreement • November 12th, 2020 • Sumitomo Chemical Co., Ltd. • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of November 12, 2020 (the “Agreement Date”), by among Urovant Sciences Ltd., a Bermuda exempted company limited by shares (the “Company”), Sumitovant Biopharma Ltd., a Bermuda exempted company limited by shares (“Parent”), Titan Ltd., a Bermuda exempted company limited by shares and a wholly owned Subsidiary of Parent (“Merger Sub”) and, solely with respect to Section 9.13 hereof, Sumitomo Dainippon Pharma Co., Ltd., a company organized under the laws of Japan (“Sumitomo”). Parent, Merger Sub and the Company are each sometimes referred to herein as a “Party” and collectively as the “Parties.” Certain capitalized terms used in this Agreement are defined in Section 9.03.
